SLC5A2 and cardiovascular disorder: This study recommended the following on the basis of the findings of this systematic review; healthcare professionals should consider incorporating SGLT2 inhibitors as part of the treatment strategy for patients with cardiovascular diseases, given the potential benefits observed in reducing the risk of major cardiovascular disorders [52,53].